Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Repare Therapeutics Inc.
< Previous
1
2
Next >
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
April 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
April 18, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
March 14, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
January 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 19, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
September 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
June 01, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
May 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
April 20, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
April 11, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
April 08, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
February 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
January 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
January 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
December 21, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
December 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 02, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
October 27, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Tickers
RPTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.